Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.

Byers B, Cord B, Nguyen HN, Schüle B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, Palmer TD.

PLoS One. 2011;6(11):e26159. doi: 10.1371/journal.pone.0026159. Epub 2011 Nov 16.

2.

Modeling Parkinson's disease using induced pluripotent stem cells.

Byers B, Lee HL, Reijo Pera R.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42. doi: 10.1007/s11910-012-0270-y. Review.

3.

Parkinson's disease in a dish - Using stem cells as a molecular tool.

Badger JL, Cordero-Llana O, Hartfield EM, Wade-Martins R.

Neuropharmacology. 2014 Jan;76 Pt A:88-96. doi: 10.1016/j.neuropharm.2013.08.035. Epub 2013 Sep 10. Review.

PMID:
24035919
4.

Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.

Beevers JE, Caffrey TM, Wade-Martins R.

Biochem Soc Trans. 2013 Dec;41(6):1503-8. doi: 10.1042/BST20130194. Review.

PMID:
24256244
5.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
6.

The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.

Yasuda T, Mochizuki H.

Apoptosis. 2010 Nov;15(11):1312-21. doi: 10.1007/s10495-010-0486-8. Review.

PMID:
20221696
7.

The central theme of Parkinson's disease: α-synuclein.

Ozansoy M, Başak AN.

Mol Neurobiol. 2013 Apr;47(2):460-5. doi: 10.1007/s12035-012-8369-3. Epub 2012 Nov 23. Review.

PMID:
23180276
8.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
9.

Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.

Luna E, Luk KC.

FEBS Lett. 2015 Dec 21;589(24 Pt A):3749-59. doi: 10.1016/j.febslet.2015.10.023. Epub 2015 Oct 23. Review.

10.

Cellular reprogramming: a new approach to modelling Parkinson's disease.

Hartfield EM, Fernandes HJ, Vowles J, Cowley SA, Wade-Martins R.

Biochem Soc Trans. 2012 Oct;40(5):1152-7. Review.

PMID:
22988881
11.

Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.

Zhang QS, Heng Y, Yuan YH, Chen NH.

Toxicol Lett. 2017 Jan 4;265:30-37. doi: 10.1016/j.toxlet.2016.11.002. Epub 2016 Nov 16. Review.

PMID:
27865851
12.

Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.

Bobela W, Aebischer P, Schneider BL.

Biomolecules. 2015 Oct 16;5(4):2675-700. doi: 10.3390/biom5042675. Review.

13.

Controlling the mass action of alpha-synuclein in Parkinson's disease.

Kim C, Lee SJ.

J Neurochem. 2008 Oct;107(2):303-16. doi: 10.1111/j.1471-4159.2008.05612.x. Epub 2008 Sep 2. Review.

14.

α-Synuclein and dopamine at the crossroads of Parkinson's disease.

Venda LL, Cragg SJ, Buchman VL, Wade-Martins R.

Trends Neurosci. 2010 Dec;33(12):559-68. doi: 10.1016/j.tins.2010.09.004. Epub 2010 Oct 18. Review.

15.

Modulation of alpha-synuclein aggregation by dopamine: a review.

Leong SL, Cappai R, Barnham KJ, Pham CL.

Neurochem Res. 2009 Oct;34(10):1838-46. doi: 10.1007/s11064-009-9986-8. Epub 2009 May 15. Review.

PMID:
19444607
16.

MicroRNAs in Parkinson's disease.

Mouradian MM.

Neurobiol Dis. 2012 May;46(2):279-84. doi: 10.1016/j.nbd.2011.12.046. Epub 2012 Jan 5. Review.

PMID:
22245218
17.

Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.

Miraglia F, Betti L, Palego L, Giannaccini G.

Cent Nerv Syst Agents Med Chem. 2015;15(2):109-16. Review.

PMID:
25896035
18.

Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.

Ferrer I, Martinez A, Blanco R, Dalfó E, Carmona M.

J Neural Transm (Vienna). 2011 May;118(5):821-39. doi: 10.1007/s00702-010-0482-8. Epub 2010 Sep 23. Review.

PMID:
20862500
19.

Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae.

Pimentel C, Batista-Nascimento L, Rodrigues-Pousada C, Menezes RA.

Oxid Med Cell Longev. 2012;2012:132146. doi: 10.1155/2012/132146. Epub 2012 Jun 3. Review.

20.

Using iPS Cells toward the Understanding of Parkinson's Disease.

Torrent R, De Angelis Rigotti F, Dell'Era P, Memo M, Raya A, Consiglio A.

J Clin Med. 2015 Mar 30;4(4):548-66. doi: 10.3390/jcm4040548. Review.

Supplemental Content

Support Center